Angiogenesis Inhibitor Therapy in Renal Cell Cancer
作者： Sarmad Sadeghi , Brian Rini
DOI: 10.1007/978-3-642-21858-3_13
关键词: Disease 、 Kidney cancer 、 Clinical trial 、 Oncology 、 Clear cell renal cell carcinoma 、 Vascular endothelial growth factor 、 Renal cell carcinoma 、 Angiogenesis inhibitor 、 Angiogenesis 、 Internal medicine 、 Medicine
摘要: The discovery of the role angiogenesis pathways in kidney cancer has significantly changed landscape this disease, particularly metastatic setting. Medications targeting vascular endothelial growth factor (VEGF), center point pathways, have given new treatment options to patients and clinicians beyond interferon therapy. This chapter provides a review history current understanding focusing on VEGF-targeting agents currently approved for use clinical practice will end with discussion newer VEGF trials.
springer.com
sci-hub.st 参考文章(60)
Gassmann M, Wenger Rh, OXYGEN(ES) AND THE HYPOXIA-INDUCIBLE FACTOR-1 Biological Chemistry. ,vol. 378, pp. 609- 616 ,(1997)
Patrick H. Maxwell, Michael S. Wiesener, Gin-Wen Chang, Steven C. Clifford, Emma C. Vaux, Matthew E. Cockman, Charles C. Wykoff, Christopher W. Pugh, Eamonn R. Maher, Peter J. Ratcliffe, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature. ,vol. 399, pp. 271- 275 ,(1999) , 10.1038/20459
Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. Journal of the National Cancer Institute. ,vol. 41, pp. 1329- 1341 ,(1968) , 10.1093/JNCI/41.6.1329
Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. Journal of the National Cancer Institute. ,vol. 41, pp. 111- 124 ,(1968) , 10.1093/JNCI/41.1.111
Judah Folkman, Ezio Merler, Charles Abernathy, Gretchen Williams, ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS Journal of Experimental Medicine. ,vol. 133, pp. 275- 288 ,(1971) , 10.1084/JEM.133.2.275
Louis M. Sherwood, Edith E. Parris, Judah Folkman, Tumor Angiogenesis: Therapeutic Implications New England Journal of Medicine. ,vol. 285, pp. 1182- 1186 ,(1971) , 10.1056/NEJM197111182852108
J. Holash, S. Davis, N. Papadopoulos, S. D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, E. Ioffe, T. Huang, C. Radziejewski, K. Bailey, J. P. Fandl, T. Daly, S. J. Wiegand, G. D. Yancopoulos, J. S. Rudge, VEGF-Trap: A VEGF blocker with potent antitumor effects Proceedings of the National Academy of Sciences of the United States of America. ,vol. 99, pp. 11393- 11398 ,(2002) , 10.1073/PNAS.172398299
H. S. N. Greene, HETEROLOGOUS TRANSPLANTATION OF HUMAN AND OTHER MAMMALIAN TUMORS Science. ,vol. 88, pp. 357- 358 ,(1938) , 10.1126/SCIENCE.88.2285.357
Susana Salceda, Jaime Caro, Hypoxia-inducible Factor 1α (HIF-1α) Protein Is Rapidly Degraded by the Ubiquitin-Proteasome System under Normoxic Conditions Journal of Biological Chemistry. ,vol. 272, pp. 22642- 22647 ,(1997) , 10.1074/JBC.272.36.22642
Steven C. Clifford, Amanda H. Prowse, Nabeel A. Affara, Charles H. C. M. Buys, Eamonn R. Maher, Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for aVHL-independent pathway in clear cell renal tumourigenesis Genes, Chromosomes and Cancer. ,vol. 22, pp. 200- 209 ,(1998) , 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#